Dai-ichi Life has invested JPY 500m ($4.6m) in Noile-Immune Biotech, a Japanese start-up that develops cancer immunotherapy.
Through this investment, the insurer hopes to provide capital support for Noile-Immune's initiatives, which are expected to extend how long cancer patients can continue to lead healthy lives.